You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Submits Comments Re: Medicare Shared Savings Program: Accountable Care Organizations Proposed Rule

<div>
Marilyn Tavenner</div>
<div>
Administrator</div>
<div>
Centers for Medicare &amp; Medicaid Services</div>
<div>
Department of Health and Human Services</div>
<div>
Room 445-G</div>
<div>
Hubert H. Humphrey Building</div>
<div>
200 Independence Avenue, S.W.</div>
<div>
Washington, D.C. 20201</div>
<div>
&nbsp;</div>
<div>
Re: Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations</div>
<div>
&nbsp;</div>
<div>
Dear Administrator Tavenner:</div>
<div>
&nbsp;</div>
<div>
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare &amp; Medicaid Services&rsquo; (CMS) proposed rule regarding the Medicare Shared Savings Program (MSSP) and Accountable Care Organizations (ACOs) (the &ldquo;Proposed Rule&rdquo;).1 BIO is the world&#39;s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of health care, agricultural, industrial, and environmental biotechnology products.</div>

Marilyn Tavenner 
Administrator
Centers for Medicare & Medicaid Services 
Department of Health and Human Services 
Room 445-G 
Hubert H. Humphrey Building
200 Independence Avenue, S.W. 
Washington, D.C. 20201
 
Re: Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations
 
Dear Administrator Tavenner:
 
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) proposed rule regarding the Medicare Shared Savings Program (MSSP) and Accountable Care Organizations (ACOs) (the “Proposed Rule”).1 BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of health care, agricultural, industrial, and environmental biotechnology products.
 
BIO represents an industry that is committed to improving health care through the discovery of novel therapies and ensuring patient access to them. We support Medicare payment policies that foster innovation and protect patient access to drugs and biologicals. Thus, we generally support growth and development of delivery of care and payment paradigms that have the potential to achieve the triple aim: provide better care for individuals, better health for populations, and lower growth in overall expenditures.